High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1309-1317

  Stiff, P J ^a   Bayer, R ^a   Kerger, C ^a   Potkul, R K ^a   Malhotra, D ^a   Peace, D J ^a   Smith, D ^a   Fisher, S G ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CA 125 ANTIGEN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; MELPHALAN; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DIARRHEA; DRUG MEGADOSE; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIVARIATE ANALYSIS; MYCOSIS; NEUROPATHY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SECOND LOOK SURGERY; STEM CELL TRANSPLANTATION;

EID: 0030901014     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1309     Document Type: Article

References (35)

1. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
2. Runowicz CD: Advances in the screening and treatment of ovarian cancer. CA 42:327-349, 1992
3. Alberts DS, Green SG, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stage III and IV ovarian cancer J Clin Oncol 10:706-717, 1992
4. McGuire WP, Hoskins WJ, Brady MF, et al: A phase III trial comparing cisplatin/Cytoxan and cisplatin/Taxol in advanced ovarian cancer. N Engl J Med 335:1-6, 1996
5. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 5:756-760, 1987
6. Levin L, Simon R, Hryniuk W: Importance of multiagent chemotherapy regimens in ovarian carcinoma: Dose intensity analysis J Natl Cancer Inst 85:1732-1742, 1993
7. Ozols RF, Thigpen JT, Dauplat J, et al: Advanced ovarian cancer. Dose intensity. Ann Oncol 4:S49-56, 1993 (suppl 4)
8. Alberts DS, Young L, Mason N, et al: In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 12:38-42, 1985 (suppl 4)
9. Lidor Y, Shapp EJ, Peters WP, et al: Alkylating agents and immunotoxins exert synergistic activity against ovarian cancer cell lines. Proc Am Assoc Cancer Res 30:401, 1989 (abstr)
10. Beherns BC, Hamilton TC, Masuda H, et al: Characterization of a cis-diamine dichloro-platinum (II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogs. Cancer Res 47:414-418, 1987
11. Teicher B, Holden SA, Jones SM, et al: Influence of scheduling in two-day combinations of alkylating agents in vivo. Cancer Chemother Pharmacol 25:161-166, 1989
12. Lidor YJ, Shpall EJ, Peters WP, et al: Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 49:704-707, 1991
13. Mulder POM, Sleijfer DT, Willemse PHB, et al: High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res 49:4654-4658, 1989
14. Shea TC, Flaherty M, Elias A, et al: A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7:651-661, 1989
15. Shpall EJ, Clark-Pearson D, Soper JT, et al: High dose alkylatmg agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol 38:386-391, 1990
16. Philip T, Armitage JG, Spitzer G, et al: High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin's lymphoma. N Engl J Med 31:1493-1498, 1987
17. Stiff P, Antman K, Broun ER, et al: Bone marrow transplantation for ovarian carcinoma in the United States: A survey of active programs, in Dicke KA, Keating A (eds): Proceedings of the Sixth International ABMT Symposium. Arlington, VA, Cancer Treatment Research Education Fund, 1993, pp 192-198
18. Stiff PJ, McKenzie RS, Alberts DS, et al: Phase I clinical and pharmacokinetic study of high-dose mtioxantrone, combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma J Clin Oncol 12:176-183, 1994
19. Stiff P, Bayer R, Camarda M, et al: A phase II trial of high dose mitoxantrone, carboplatin. and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis of risk factors for clinical outcome. Gynecol Oncol 57:278-285, 1995.
20. Stiff PJ, Bayer R, Tan S, et al: High-dose chemotherapy combined with escalating doses of cyclosporin a and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: A phase I clinical trial. Clin Cancer Res 1:1495-1502, 1995
21. Stiff PJ, Koester AR, Weidner MK, et al: Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled rate freezing. Blood 70:974-978, 1987
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
24. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian cancer after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994
25. Gordon A, Bookman M, Malmstrom H, et al: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:282, 1996 (abstr)
26. Yancik R, Ries LG, Yates JW: Ovarian cancer in the elderly: An analysis of Surveillance, Epidemiology and End Results program data. Am J Obstet Gynecol 154:639-647, 1986
27. Yancik R: Ovarian cancer: Age contrast in incidence, biology, disease stage at diagnosis, and mortality. Cancer 71:517S-523S, 1993
28. Thigpen T, Brady MF, Omura GA, et al: Age as a prognostic factor in ovarian cancer. Cancer 71:606S-614S, 1993
29. Gershenson DM, Mitchell MF, Atkinson N, et al: Age contrasts in patients with advanced epithelial ovarian cancer. Cancer 71:638S-643S, 1993
30. Edwards BP, Lembersky BC, Kunschner AJ, et al: Intraperitoneal interleukin-2 produces durable responses for refractory ovarian cancer. Proc Am Soc Clin Oncol 14:333, 1995 (abstr)
31. Pujade-Lauraine E, Guastalla JP, Colombo N, et al: Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14:343-350, 1996
32. Dauplat J, Legros M, Condat P, et al: High dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operation. Gynecol Oncol 34:294-298, 1989
33. Legros M, Fluery J, Cure H, et al: High dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT) in 31 advanced ovarian cancers: Long term results. Proc Am Soc Clin Oncol 11:222, 1992 (abstr)
34. Viens P, Maraninchi D, Legros M, et al: High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France. Bone Marrow Transplant 5:227-233, 1990
35. Extra JM, Giacchetti S, Bourstyn, et al: High dose chemotherapy with autologous bone marrow reinfusion as consolidation therapy for patients with advanced ovarian adenocarcinoma. Proc Am Soc Clin Oncol 11:234, 1992 (abstr)